Understanding and reverting the epigenetic reprogramming of bone marrow stroma cells in myelodysplastic syndromes (WP2)
Rationale and objectives
Epigenetic changes contribute to a switch in the preferential support of myelodysplastic syndromes (MDS) and secondary-type acute myeloid leukaemia (sAML) haematopoietic stem cell/progenitors (HSPCs) over healthy HSPCs by bone marrow (BM) stroma cells.
Our objectives are:
• To establish a three-component co-culture system of disease HSPCs, healthy HSPCs and stroma cells.
• To identify chromatin regulators in stroma cells that sustain a transcriptional program favoring disease HSPC support.
• To understand how most-disease relevant chromatin regulators exert their function.
Klinikum rechts der Isar der TU München and Institute for Tumor Biology and Experimental Therapy, Georg-Speyer-Haus (Germany, 3 months). Depending on the project development: Aelian Bio (Austria, 1 month).
PhD in Cell Biology, Autonomous University of Barcelona (UAB), Spain.